SLNO - Company ID 0001484565
The table below shows SOLENO THERAPEUTICS INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $94.60M | $66.02M | $32.66M | - | - | - |
| Cost of revenue | $1.20M | $1.14M | $696.00K | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $11.27M | $8.40M | $9.15M | $13.52M | $30.14M | $12.34M |
SOLENO THERAPEUTICS INC reported annual revenue of $190.41M for fiscal year 2025. That is up 13024.2% from $1.45M in fiscal 2016. Over the 5 fiscal years shown, annual revenue grew from $3.00M (FY 2013) to $190.41M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $50.37M |
| $33.75M |
| $28.24M |
| $29.26M |
| $49.20M |
| $10.89M |
| Operating income | $31.28M | $22.11M | -$6.53M | -$45.74M | -$80.21M | -$24.87M |
| Income tax | $3.54M | - | - | $0.00 | - | - |
| Net income | $31.38M | $26.01M | -$4.71M | -$43.77M | -$76.62M | -$21.85M |
| EPS (diluted) | $0.59 | $0.47 | -$0.09 | -$0.95 | -$1.83 | -$0.57 |